Myeloproliferative Neoplasms (MPNs)
[Excluding CML]

Primary Myelofibrosis (PMF)
- Previously enrolled in HEMMPD0020 or HEMMPD0018
  - HEMMPD0031 Phase II Luspatercept (ACF-539) in Myeloproliferative Neoplasm-Associated Myelofibrosis & Anemia +/-
    - PI: Goliib Celgene
  - HEMMPD0030 Phase II Pacritinib in Myeloproliferative Disorders Previously Treated with Ruxolitinib
    - PI: Goliib CTI Biopharma
- Progressed /Intolerant on JAK

Aggressive Systemic Mastocytosis/ Mast Cell Leukemia
- CD30-:
  - HEMMPD0034 Phase II Avapritinib (BLU-285) KIT Mutation-targeted TKI in Advanced Systemic Mastocytosis
    - PI: Goliib 1st Priority
  - HEMMPD0037 Phase I BLU-285 in Advanced Systemic Mastocytosis (advSM) & Relapsed /Refractory Myeloid Malignancies
    - PI: Goliib 2nd Priority
  - HEMMPD0029 Phase I DCC-2618 in Advanced Malignancies
    - PI: Goliib 3rd Priority

Chronic Neutrophilic Leukemia (CNL) and Atypical Chronic Myeloid Leukemia (CML)
- HEMMPD0022 Phase II Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR
  - PI: Goliib OHSU Knight Cancer Center
- FGFR1 Rearrangement
  - HEMMPD0028 Phase II INCB054828 in Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
    - PI: Goliib Incyte Corporation

**KEY**
- Pending
- Open for Enrollment
- Observation Study
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy

*Please mark up a copy using black ink and email changes to SRC-office@stanford.edu*